Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology in Practice
  3. Anti-Cancer Agents and Biological Therapy
  4. Targeting NTRK Gene Fusions
  5. Importance of Testing Cancers for NTRK Gene Fusions
  6. General Challenges of Testing for Cancers With NTRK Gene Fusion
  7. Other Techniques
  8. Nanostring

Nanostring

Previous Page Next Page

Application

Nanostring may be a useful test to replace some clinically available FISH and RT-PCR assays as the initial molecular diagnostic for NTRK gene fusion testing due to its cost effectiveness, short assay turnaround time, and ease of data analysis [1].

References

  1. Chang KTE, Goytain A, Tucker T et al. Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. J Mol Diagn 2018; 20: 63-77.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.